Research programme: cholecystokinin receptor modulators - Johnson & Johnson

Drug Profile

Research programme: cholecystokinin receptor modulators - Johnson & Johnson

Alternative Names: CCK-1 receptor antagonists - Johnson & Johnson; CCK-2 receptor modulators - Johnson & Johnson; CCK-2/gastrin receptor antagonists - Johnson & Johnson; CCK-B receptor antagonists - Johnson & Johnson; CCK-B receptor modulators - Johnson & Johnson; JNJ-26070109; Oral CCK-2 antagonists - Johnson & Johnson Pharmaceutical Research & Development LLC

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Johnson & Johnson Pharmaceutical Research & Development
  • Developer Janssen Research & Development
  • Class Small molecules
  • Mechanism of Action Cholecystokinin A receptor antagonists; Cholecystokinin B receptor antagonists; Cholecystokinin B receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • No development reported Gastro-oesophageal reflux; Gastrointestinal disorders; Pancreatitis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Pancreatitis in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastro-oesophageal-reflux in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top